Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mild-To-Moderate Alzheimer's Disease Clear all

Conditions: Alzheimer's Disease
Interventions: ABT-957, Placebo for ABT-957; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Glendale, California • Orlando, Florida • New York, New York + 1 more

Conditions: Alzheimer Disease
Interventions: Salsalate, Placebo; Drug
Lead sponsor: Adam Boxer; Other
Eligibility: 50 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Alzheimer's Disease
Interventions: PF-05212377 (SAM-760), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more

Conditions: Alzheimer Disease
Interventions: Simufilam; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 51 Years to 89 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 107
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more

Conditions: Alzheimer's Disease
Interventions: Placebo, RO5313534; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Orange, California • Torrance, California • Norwalk, Connecticut + 11 more

Conditions: Alzheimer Disease
Interventions: lecozotan SR (SRA-333); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more

Conditions: Alzheimer Disease
Interventions: Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 37
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more

Conditions: Alzheimer Disease
Interventions: NP001, Placebo; Drug
Lead sponsor: Beau Nakamoto; Other
Eligibility: 55 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Alzheimer Disease
Interventions: Approximately 100 million cells allogeneic hMSC; Biological
Lead sponsor: Bernard (Barry) Baumel; Other
Eligibility: 50 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer's Disease
Interventions: PPI-1019 (APAN); Drug
Lead sponsor: PRAECIS Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Orange, California • Princeton, New Jersey

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg; Drug
Lead sponsor: GemVax & Kael; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more

Conditions: Dementia Alzheimer's Type
Interventions: SAR110894, placebo (for SAR110894), Donepezil; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more

Conditions: Alzheimer's Disease
Interventions: LY2062430, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more

Conditions: Alzheimer Disease
Interventions: 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos; Drug
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 93
States / cities: Mobile, Alabama • Northport, Alabama • Little Rock, Arkansas + 82 more

Conditions: Alzheimer's Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 40
States / cities: Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more

Conditions: Alzheimer's Disease
Interventions: ABT-126; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Delray Beach, Florida • West Palm Beach, Florida • Elk Grove Village, Illinois + 2 more

Conditions: Alzheimer Disease
Interventions: Daratumumab Injection; Drug
Lead sponsor: Marc L Gordon, MD; Other
Eligibility: 55 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Alzheimer's Disease
Interventions: MABT5102A, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more

Conditions: Alzheimer Disease
Interventions: AVE1625; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: ORY-2001 Low dose, ORY-2001 High dose, Placebo; Drug
Lead sponsor: Oryzon Genomics S.A.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Wellington, Florida • Columbus, Georgia • Princeton, New Jersey + 1 more

Conditions: Alzheimer Disease
Interventions: memantine; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Alzheimer's Disease
Interventions: Albutein 5%, Control; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Whiting, New Jersey

Conditions: Alzheimer's Disease
Interventions: Coconut Oil Beverage, Placebo Beverage; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 55 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Open-label Extension for Phase 3 Clinical Trials of Simufilam

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer's Disease Stem Cells Multiple Infusions

Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

Study to Evaluate Coconut Oil for Alzheimer's Disease